{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:17:07Z","timestamp":1784557027914,"version":"3.55.0"},"reference-count":37,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ec.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fibroblast growth factor 23 (FGF23) is a key regulator of urine phosphate excretion. The aim of the study was to investigate the perioperative (intraoperative and postoperative) changes of plasma intact and C-terminal FGF23 (iFGF23, cFGF23) concentrations in patients with primary hyperparathyroidism (pHPT) submitted to surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>The study involved 38 adult patients with pHPT caused by adenoma. Parathyroid hormone (PTH) levels were investigated intraoperatively (just before the incision and 10 min after adenoma excision). cFGF23, iFGF23, phosphate, estimated glomerular filtration rate (eGFR), and procollagen type 1 N-terminal propetide (P1NP) were measured intraoperatively and postoperatively (next day after the surgery).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      PTH levels decreased intraoperatively (13.10 pmol\/L vs 4.17 pmol\/L,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.0001). FGF23 levels measured intraoperatively were at the upper level of reference interval. cFGF23 decreased postoperatively compared with the values measured just before the incision (cFGF23: 89.17 RU\/mL vs 22.23 RU\/mL,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.0001). iFGF23 decreased as well, but the postoperative values were low. Postoperative inorganic phosphate values increased (1.03 mmol\/L vs 0.8 mmol\/L,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.0025). We proved significant negative correlation of perioperative FGF23 with inorganic phosphate (cFGF23: Spearman\u2019s r\u2009=\u2009\u22120.253,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.0065; iFGF23: Spearman\u2019s r\u2009=\u2009\u22120.245,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.0085). We also found that FGF23 values just before incision correlated with eGFR (cystatin C) (cFGF23: Spearman\u2019s r\u2009=\u2009\u22120.499,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.0014; iFGF23: Spearman\u2019s r\u2009=\u2009\u22120.413,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Intraoperative iFGF23 and cFGF23 did not change despite PTH decreased significantly. cFGF23 and iFGF23 significantly decreased 1 day after parathyroidectomy and are associated with increase of inorganic phosphate in pHPT patients. cFGF23 and iFGF23 just before incision correlated with eGFR (cystatin C). Similar results found in both iFGF23 and cFGF23 suggest that each could substitute the other.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/ec-21-0430","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T10:36:05Z","timestamp":1638527765000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":3,"title":["Perioperative changes of FGF23 in patients undergoing surgery for primary hyperparathyroidism"],"prefix":"10.1530","volume":"11","author":[{"given":"Magdal\u00e9na","family":"Fo\u0159tov\u00e1","sequence":"first","affiliation":[{"name":"Department of Medical Chemistry and Clinical Biochemistry, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Hanouskov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Medical Chemistry and Clinical Biochemistry, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Valkus","sequence":"additional","affiliation":[{"name":"Department of Medical Chemistry and Clinical Biochemistry, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"\u010cepov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Medical Chemistry and Clinical Biochemistry, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Pr\u016f\u0161a","sequence":"additional","affiliation":[{"name":"Department of Medical Chemistry and Clinical Biochemistry, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Kota\u0161ka","sequence":"additional","affiliation":[{"name":"Department of Medical Chemistry and Clinical Biochemistry, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Tietz Textbook of Clinical Chemistry and Molecular Diagnostics","author":"Rifai","year":"2018","unstructured":"Rifai NHorvath AWittwer C. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. St. Louis: Elsevier, 2018."},{"key":"bib2","series-title":"Surgery","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.surg.2015.06.057","article-title":"FGF23, metabolic risk factors, and blood pressure in patients with primary hyperparathyroidism undergoing parathyroid adenomectomy","volume":"159","author":"Nilsson","year":"2016","unstructured":"Nilsson ILNorenstedt SGranath FZedenius JPernow YLarsson TE. FGF23, metabolic risk factors, and blood pressure in patients with primary hyperparathyroidism undergoing parathyroid adenomectomy. Surgery2016159211\u2013217. (https:\/\/doi.org\/10.1016\/j.surg.2015.06.057)10.1016\/j.surg.2015.06.057"},{"key":"bib3","series-title":"European Journal of Endocrinology","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1530\/EJE-11-0523","article-title":"Increased circulating levels of FGF23: an adaptive response in primary hyperparathyroidism?","volume":"166","author":"Witteveen","year":"2012","unstructured":"Witteveen JEvan Lierop AHPapapoulos SEHamdy NA. Increased circulating levels of FGF23: an adaptive response in primary hyperparathyroidism?European Journal of Endocrinology201216655\u201360. (https:\/\/doi.org\/10.1530\/EJE-11-0523)10.1530\/EJE-11-0523"},{"key":"bib4","series-title":"Kidney International: Supplement","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1038\/ki.2011.27","article-title":"Phosphate and FGF-23","volume":"79","author":"Juppner","year":"2011","unstructured":"Juppner HPhosphate and FGF-23. Kidney International: Supplement201179S24\u2013S27. (https:\/\/doi.org\/10.1038\/ki.2011.27)10.1038\/ki.2011.27"},{"key":"bib5","series-title":"Trends in Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.tem.2009.02.001","article-title":"Bone as an endocrine organ","volume":"20","author":"Fukumoto","year":"2009","unstructured":"Fukumoto SMartin TJ. Bone as an endocrine organ. Trends in Endocrinology and Metabolism200920230\u2013236. (https:\/\/doi.org\/10.1016\/j.tem.2009.02.001)10.1016\/j.tem.2009.02.001"},{"key":"bib6","series-title":"Journal of Bone and Mineral Metabolism","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00774-011-0340-2","article-title":"The expanding family of hypophosphatemic syndromes","volume":"30","author":"Carpenter","year":"2012","unstructured":"Carpenter TOThe expanding family of hypophosphatemic syndromes. Journal of Bone and Mineral Metabolism2012301\u20139. (https:\/\/doi.org\/10.1007\/s00774-011-0340-2)10.1007\/s00774-011-0340-2"},{"key":"bib7","series-title":"Frontiers in Endocrinology","article-title":"Osteocytic FGF23 and its kidney function","volume":"11","author":"Agoro","year":"2020","unstructured":"Agoro RNi PNoonan MLWhite KE. Osteocytic FGF23 and its kidney function. Frontiers in Endocrinology202011 592. (https:\/\/doi.org\/10.3389\/fendo.2020.00592)"},{"key":"bib8","series-title":"Kidney International","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/ki.2013.534","article-title":"Enigmatic Cassandra: renal FGF23 formation in polycystic kidney disease","volume":"85","author":"Lang","year":"2014","unstructured":"Lang FFoller M. Enigmatic Cassandra: renal FGF23 formation in polycystic kidney disease. Kidney International2014851260\u20131262. (https:\/\/doi.org\/10.1038\/ki.2013.534)10.1038\/ki.2013.534"},{"key":"bib9","series-title":"Scientific Reports","article-title":"FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts","volume":"7","author":"Smith","year":"2017","unstructured":"Smith ERTan SJHolt SGHewitson TD. FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts. Scientific Reports20177 3345. (https:\/\/doi.org\/10.1038\/s41598-017-02709-w)"},{"key":"bib10","series-title":"Calcified Tissue International","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00223-020-00705-3","article-title":"New therapies for hypophosphatemia-related to FGF23 excess","volume":"108","author":"Athonvarangkul","year":"2021","unstructured":"Athonvarangkul DInsogna KL. New therapies for hypophosphatemia-related to FGF23 excess. Calcified Tissue International2021108143\u2013157. (https:\/\/doi.org\/10.1007\/s00223-020-00705-3)10.1007\/s00223-020-00705-3"},{"key":"bib11","series-title":"JBMR Plus","article-title":"FGF23, hypophosphatemia, and emerging treatments","volume":"3","author":"Imel","year":"2019","unstructured":"Imel EABiggin ASchindeler AMunns CF. FGF23, hypophosphatemia, and emerging treatments. JBMR Plus20193 e10190. (https:\/\/doi.org\/10.1002\/jbm4.10190)"},{"key":"bib12","series-title":"Physiological Reviews","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1152\/physrev.00002.2011","article-title":"Regulation and function of the FGF23\/klotho endocrine pathways","volume":"92","author":"Martin","year":"2012","unstructured":"Martin ADavid VQuarles LD. Regulation and function of the FGF23\/klotho endocrine pathways. Physiological Reviews201292131\u2013155. (https:\/\/doi.org\/10.1152\/physrev.00002.2011)10.1152\/physrev.00002.2011"},{"key":"bib13","series-title":"Clinical Journal of the American Society of Nephrology","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.2215\/CJN.04290511","article-title":"Fibroblast growth factor 23 in patients undergoing peritoneal dialysis","volume":"6","author":"Isakova","year":"2011","unstructured":"Isakova TXie HBarchi-Chung AVargas GSowden NHouston JWahl PLundquist AEpstein MSmith KFibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clinical Journal of the American Society of Nephrology201162688\u20132695. (https:\/\/doi.org\/10.2215\/CJN.04290511)10.2215\/CJN.04290511"},{"key":"bib14","series-title":"Experimental Cell Research","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.yexcr.2012.02.027","article-title":"Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease","volume":"318","author":"Quarles","year":"2012","unstructured":"Quarles LDRole of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Experimental Cell Research20123181040\u20131048. (https:\/\/doi.org\/10.1016\/j.yexcr.2012.02.027)10.1016\/j.yexcr.2012.02.027"},{"key":"bib15","series-title":"Seminars in Nephrology","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.semnephrol.2012.12.014","article-title":"A systems biology preview of the relationships between mineral and metabolic complications in chronic kidney disease","volume":"33","author":"Quarles","year":"2013","unstructured":"Quarles LDA systems biology preview of the relationships between mineral and metabolic complications in chronic kidney disease. Seminars in Nephrology201333130\u2013142. (https:\/\/doi.org\/10.1016\/j.semnephrol.2012.12.014)10.1016\/j.semnephrol.2012.12.014"},{"key":"bib16","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"E652","DOI":"10.1210\/jc.2013-4050","article-title":"Impact of parathyroidectomy on serum FGF23 and soluble klotho in hemodialysis patients with severe secondary hyperparathyroidism","volume":"99","author":"Takahashi","year":"2014","unstructured":"Takahashi HKomaba HTakahashi YSawada KTatsumi RKanai GSuzuki HKakuta TFukagawa M. Impact of parathyroidectomy on serum FGF23 and soluble klotho in hemodialysis patients with severe secondary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism201499E652\u2013E658. (https:\/\/doi.org\/10.1210\/jc.2013-4050)10.1210\/jc.2013-4050"},{"key":"bib17","series-title":"Endocrine-Related Cancer","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1530\/ERC-11-0006","article-title":"Tumor-induced osteomalacia","volume":"18","author":"Chong","year":"2011","unstructured":"Chong WHMolinolo AAChen CCCollins MT. Tumor-induced osteomalacia. Endocrine-Related Cancer201118R53\u2013R77. (https:\/\/doi.org\/10.1530\/ERC-11-0006)10.1530\/ERC-11-0006"},{"key":"bib18","series-title":"Current Osteoporosis Reports","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s11914-014-0223-2","article-title":"Hypophosphatemic rickets: revealing novel control points for phosphate homeostasis","volume":"12","author":"White","year":"2014","unstructured":"White KEHum JMEcons MJ. Hypophosphatemic rickets: revealing novel control points for phosphate homeostasis. Current Osteoporosis Reports201412252\u2013262. (https:\/\/doi.org\/10.1007\/s11914-014-0223-2)10.1007\/s11914-014-0223-2"},{"key":"bib19","article-title":"Human FGF-23 (C-term) ELISA kit 2nd generation enzyme-linked immunosorbent assay (ELISA) for the determination of human fibroblast growth factor 23 levels in plasma or cell culture media","year":"2020","unstructured":"Immutopics. Human FGF-23 (C-term) ELISA kit 2nd generation enzyme-linked immunosorbent assay (ELISA) for the determination of human fibroblast growth factor 23 levels in plasma or cell culture media. San Clemente, CA, USA : Immutopics, 2020."},{"key":"bib20","article-title":"Human FGF-23 (intact) ELISA kit 2nd generation enzyme-linked immunosorbent assay (ELISA) for the quantitative determination of human fibroblast growth factor 23 levels in plasma or cell culture media","year":"2020","unstructured":"Immutopics. Human FGF-23 (intact) ELISA kit 2nd generation enzyme-linked immunosorbent assay (ELISA) for the quantitative determination of human fibroblast growth factor 23 levels in plasma or cell culture media. San Clemente, CA, USA: Immutopics, 2020."},{"key":"bib21","series-title":"Annals of Clinical Biochemistry","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/0004563213510708","article-title":"Fibroblast growth factor 23","volume":"51","author":"Smith","year":"2014","unstructured":"Smith ERMcMahon LPHolt SG. Fibroblast growth factor 23. Annals of Clinical Biochemistry201451203\u2013227. (https:\/\/doi.org\/10.1177\/0004563213510708)10.1177\/0004563213510708"},{"key":"bib22","series-title":"Clinical Chemistry","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1373\/clinchem.2013.206649","article-title":"Pathophysiological implications of fibroblast growth factor-23 and klotho and their potential role as clinical biomarkers","volume":"60","author":"Donate-Correa","year":"2014","unstructured":"Donate-Correa JMuros de Fuentes MMora-Fernandez CNavarro-Gonzalez JF. Pathophysiological implications of fibroblast growth factor-23 and klotho and their potential role as clinical biomarkers. Clinical Chemistry201460933\u2013940. (https:\/\/doi.org\/10.1373\/clinchem.2013.206649)10.1373\/clinchem.2013.206649"},{"key":"bib23","series-title":"Kidney and Blood Pressure Research","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1159\/000443452","article-title":"C-terminal to intact fibroblast growth factor 23 ratio in relation to estimated glomerular filtration rate in elderly population","volume":"41","author":"Bozentowicz-Wikarek","year":"2016","unstructured":"Bozentowicz-Wikarek MOwczarek AKocelak POlszanecka-Glinianowicz MWiecek AChudek J. C-terminal to intact fibroblast growth factor 23 ratio in relation to estimated glomerular filtration rate in elderly population. Kidney and Blood Pressure Research201641519\u2013526. (https:\/\/doi.org\/10.1159\/000443452)10.1159\/000443452"},{"key":"bib24","series-title":"European Journal of Endocrinology","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1530\/eje.1.02053","article-title":"Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism","volume":"154","author":"Kobayashi","year":"2006","unstructured":"Kobayashi KImanishi YMiyauchi AOnoda NKawata TTahara HGoto HMiki TIshimura ESugimoto TRegulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. European Journal of Endocrinology200615493\u201399. (https:\/\/doi.org\/10.1530\/eje.1.02053)10.1530\/eje.1.02053"},{"key":"bib25","series-title":"Therapeutic Advances in Endocrinology and Metabolism","first-page":"2042018821995370","article-title":"Normocalcaemic primary hyperparathyroidism: what is the role of parathyroid surgery?","volume":"12","author":"Aojula","year":"2021","unstructured":"Aojula NKhan SGittoes NHassan-Smith Z. Normocalcaemic primary hyperparathyroidism: what is the role of parathyroid surgery?Therapeutic Advances in Endocrinology and Metabolism2021122042018821995370. (https:\/\/doi.org\/10.1177\/2042018821995370)"},{"key":"bib26","series-title":"Cold Spring Harbor Perspectives in Medicine","doi-asserted-by":"publisher","first-page":"a031260","DOI":"10.1101\/cshperspect.a031260","article-title":"Biology of fibroblast growth factor 23: from physiology to pathology","volume":"8","author":"Courbebaisse","year":"2018","unstructured":"Courbebaisse MLanske B. Biology of fibroblast growth factor 23: from physiology to pathology. Cold Spring Harbor Perspectives in Medicine20188a031260. (https:\/\/doi.org\/10.1101\/cshperspect.a031260)10.1101\/cshperspect.a031260"},{"key":"bib27","series-title":"Nefrologia","first-page":"392","article-title":"FGF23: a key player in mineral and bone disorder in CKD","volume":"29","author":"Komaba","year":"2009","unstructured":"Komaba HFukagawa M. FGF23: a key player in mineral and bone disorder in CKD. Nefrologia200929392\u2013396. (https:\/\/doi.org\/10.3265\/Nefrologia.2009.29.5.5400.en.full)"},{"key":"bib28","series-title":"Nefrologia","first-page":"275","article-title":"FGF23 and mineral metabolism, implications in CKD-MBD","volume":"32","author":"Rodriguez","year":"2012","unstructured":"Rodriguez MLopez IMunoz JAguilera-Tejero EAlmaden Y. FGF23 and mineral metabolism, implications in CKD-MBD. Nefrologia201232275\u2013278. (https:\/\/doi.org\/10.3265\/Nefrologia.pre2012.Mar.11415)"},{"key":"bib29","series-title":"European Journal of Endocrinology","first-page":"55","article-title":"Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism","volume":"151","author":"Yamashita","year":"2004","unstructured":"Yamashita HYamashita TMiyamoto MShigematsu TKazama JJShimada TYamazaki YFukumoto SFukagaw MNoguchi S. Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. European Journal of Endocrinology200415155\u201360. (https:\/\/doi.org\/10.1530\/eje.0.1510055)"},{"key":"bib30","series-title":"BMC Nephrology","article-title":"Discrepant glomerular filtration rate trends from creatinine and cystatin C in patients with chronic kidney disease: results from the KNOW-CKD cohort","volume":"21","author":"Kang","year":"2020","unstructured":"Kang EHan SSKim JPark SKChung WOh YKChae DWKim YSAhn COh KH. Discrepant glomerular filtration rate trends from creatinine and cystatin C in patients with chronic kidney disease: results from the KNOW-CKD cohort. BMC Nephrology202021 280. (https:\/\/doi.org\/10.1186\/s12882-020-01932-4)"},{"key":"bib31","series-title":"European Journal of Endocrinology","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1530\/EJE-15-0341","article-title":"Estimated glomerular filtration rate by serum cystatin C correlates with cardiometabolic parameters in patients with primary hyperparathyroidism","volume":"173","author":"Ermetici","year":"2015","unstructured":"Ermetici FFilopanti MVerga UPasseri EDito GMalavazos AEMapelli CRaggi MESpada ACorbetta S. Estimated glomerular filtration rate by serum cystatin C correlates with cardiometabolic parameters in patients with primary hyperparathyroidism. European Journal of Endocrinology2015173441\u2013446. (https:\/\/doi.org\/10.1530\/EJE-15-0341)10.1530\/EJE-15-0341"},{"key":"bib32","series-title":"Endokrynologia Polska","first-page":"306","article-title":"FGF23 and primary hyperparathyroidism: is there a link?","volume":"71","author":"Bilha","year":"2020","unstructured":"Bilha SCGatu AAVelicescu CBilha AFlorescu ABranisteanu D. FGF23 and primary hyperparathyroidism: is there a link?Endokrynologia Polska202071306\u2013312. (https:\/\/doi.org\/10.5603\/EP.a2020.0030)"},{"key":"bib33","series-title":"International Journal of General Medicine","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2147\/IJGM.S253246","article-title":"Evaluation of serum level of FGF23 and 1,25(OH)2D3 in primary hyperparathyroidism patients before and after parathyroidectomy","volume":"13","author":"Hassani","year":"2020","unstructured":"Hassani SAfkhamizadeh MTeimouri ANajaf Najafi MVazifeh Mostaan LMohebbi M. Evaluation of serum level of FGF23 and 1,25(OH)2D3 in primary hyperparathyroidism patients before and after parathyroidectomy. International Journal of General Medicine202013289\u2013295. (https:\/\/doi.org\/10.2147\/IJGM.S253246)10.2147\/IJGM.S253246"},{"key":"bib34","series-title":"Contributions to Nephrology","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000468952","article-title":"Fibroblast growth factor 23: mineral metabolism and beyond","volume":"190","author":"Grabner","year":"2017","unstructured":"Grabner AMazzaferro SCianciolo GKrick SCapelli IRotondi SRonco CLa Manna GFaul C. Fibroblast growth factor 23: mineral metabolism and beyond. Contributions to Nephrology201719083\u201395. (https:\/\/doi.org\/10.1159\/000468952)10.1159\/000468952"},{"key":"bib35","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1210\/jc.2009-1603","article-title":"Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active","volume":"95","author":"Shimada","year":"2010","unstructured":"Shimada TUrakawa IIsakova TYamazaki YEpstein MWesseling-Perry KWolf MSalusky IBJ\u00fcppner H. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. Journal of Clinical Endocrinology and Metabolism201095578\u2013585. (https:\/\/doi.org\/10.1210\/jc.2009-1603)10.1210\/jc.2009-1603"},{"key":"bib36","series-title":"Nature Reviews: Nephrology","first-page":"7","article-title":"FGF23 at the crossroads of phosphate, iron economy and erythropoiesis","volume":"16","author":"Edmonston","year":"2020","unstructured":"Edmonston DWolf M. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. Nature Reviews: Nephrology2020167\u201319. (https:\/\/doi.org\/10.1038\/s41581-019-0189-5)"},{"key":"bib37","series-title":"Blood Advances","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1182\/bloodadvances.2020001595","article-title":"Interplay of erythropoietin, fibroblast growth factor 23, and erythroferrone in patients with hereditary hemolytic anemia","volume":"4","author":"van Vuren","year":"2020","unstructured":"van Vuren AJEisenga MFvan Straaten SGlenthoj AGaillard CAJMBakker SJLde Borst MHvan Wijk Rvan Beers EJ. Interplay of erythropoietin, fibroblast growth factor 23, and erythroferrone in patients with hereditary hemolytic anemia. Blood Advances202041678\u20131682. (https:\/\/doi.org\/10.1182\/bloodadvances.2020001595)10.1182\/bloodadvances.2020001595"}],"container-title":["Endocrine Connections"],"original-title":[],"link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/11\/1\/EC-21-0430.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/11\/1\/EC-21-0430.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/11\/1\/EC-21-0430.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:44:54Z","timestamp":1784555094000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/ec\/article\/921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":37,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/ec-21-0430","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,1]]}}}